New long-term follow-up analysis of the JUPITER-02 trial reveals toripalimab plus chemotherapy as a highly effective 1st-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC), achieving a median OS of 64.8 months and a 5-year OS rate of 52.3%. Similarly, the final analysis of JUPITER-06 confirms the survival benefit of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC), with a median OS of 17.7 months and a 3-year OS rate of 29.7%. These results were presented at the ESMO Asia 2025 Congress and establish toripalimab as a new standard of care for these cancer types. Junshi Biosciences, the developer of toripalimab, expressed excitement over these groundbreaking findings.

Read more at GlobeNewswire: Toripalimab Presents Long-Term Survival Benefits as